文献速递妇科

瑞格列克联合治疗在子宫肌瘤和子宫腺肌病女性中的疗效与安全性:LIBERTY 1和LIBERTY 2亚组分析

Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2.
PubMed 文献 · Fertil Steril · 2025-05-02

该事后分析汇总LIBERTY 1和LIBERTY 2研究完成者数据,比较合并超声诊断子宫腺肌病的子宫肌瘤女性与总体研究人群。111例(18.2%)合并子宫腺肌病,瑞格列克联合治疗组治疗应答者83.8%、安慰剂组27.6%,闭经率分别为64.9%和6.9%。结论认为该亚组疗效与总体人群相当。

要点

  • 合并子宫腺肌病患者中瑞格列克联合治疗组治疗应答者占83.8%,安慰剂组占27.6%。
  • 瑞格列克联合治疗组闭经率64.9%,安慰剂组6.9%。
  • 瑞格列克联合治疗组子宫体积最小二乘均值下降22.2%,安慰剂组下降5.8%。

核心结论

  • 合并子宫腺肌病和子宫肌瘤女性的疗效结局与LIBERTY总体研究人群相当。

研究设计与样本

  • 本事后分析使用LIBERTY关键研究完成者的汇总数据,将合并子宫腺肌病和子宫肌瘤的亚组与总体研究人群在选定疗效和安全性终点上进行比较。
  • 受试者为18-50岁绝经前女性,经超声确诊子宫肌瘤,并经碱性血红素法评估存在月经过多。
  • 干预为每日一次瑞格列克联合治疗(瑞格列克40 mg、雌二醇1 mg和醋酸炔诺酮0.5 mg)或安慰剂治疗24周,或延迟瑞格列克联合治疗(瑞格列克40 mg单药治疗12周,随后瑞格列克联合治疗12周)。

主要发现

  • 共111例女性(18.2%)基线诊断为合并子宫腺肌病并纳入本分析(瑞格列克联合治疗组37例,延迟瑞格列克联合治疗组45例,安慰剂组29例)。
  • 子宫腺肌病女性中,瑞格列克联合治疗组治疗应答者占83.8%,安慰剂组占27.6%。
  • 子宫腺肌病女性中,瑞格列克联合治疗组64.9%达到闭经,安慰剂组为6.9%。
  • 子宫腺肌病女性子宫体积最小二乘均值在瑞格列克联合治疗组和安慰剂组分别下降22.2%和5.8%。
  • 上述结局在瑞格列克联合治疗人群中的结果与延迟瑞格列克联合治疗组相似。

关键数值与推荐

  • 治疗应答者定义为在治疗最后35天内达到或维持月经失血量<80 mL且月经失血量体积较基线减少≥50%。
  • 闭经定义为在治疗最后35天内达到或维持闭经。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the effects of relugolix combination therapy in women with uterine fibroids (UFs) and concomitant ultrasound-diagnosed adenomyosis. DESIGN: This post hoc analysis used pooled data from completers of the pivotal LIBERTY studies. The subgroup of women with adenomyosis and UFs was compared with the overall study population on selected efficacy and safety endpoints. SUBJECTS: Premenopausal women (aged 18-50 years) with diagnosed UFs (confirmed by ultrasonography) and heavy menstrual bleeding (assessed by the alkaline hematin method). INTERVENTION: Once-daily relugolix combination therapy (40 mg relugolix, 1 mg estradiol, and 0.5 mg of norethindrone acetate) or placebo for 24 weeks, or delayed relugolix combination therapy (40 mg of relugolix monotherapy for 12 weeks, followed by relugolix combination therapy for 12 weeks). MAIN OUTCOME MEASURES: Endpoints included the percentage of women with concomitant adenomyosis, the proportion of treatment responders (achieved or maintained a menstrual blood loss <80 mL and ≥50% reduction in menstrual blood loss volume from baseline over the last 35 days of treatment), the proportion of women achieving or maintaining amenorrhea over the last 35 days of treatment, and the change from baseline to week 24 in uterine volume and adverse events. RESULTS: A total of 111 women (18.2%) had a baseline diagnosis of concomitant adenomyosis (37 in the relugolix combination therapy group, 45 in the delayed relugolix combination therapy group, 29 in the placebo group) and were included in this analysis. Of women with adenomyosis, 83.8% in the relugolix combination therapy group were treatment responders compared with 27.6% in the placebo group. Amenorrhea was achieved in 64.9% of women with adenomyosis treated with relugolix combination therapy and in 6.9% of women treated with placebo. The least square mean uterine volume of women with adenomyosis decreased by 22.2% and 5.8% in the relugolix combination therapy and placebo groups, respectively. Results for the above outcomes in the relugolix combination therapy population were similar to the delayed relugolix combination therapy group. CONCLUSION: Efficacy outcomes in women with adenomyosis and UFs were comparable with those in women from the overall LIBERTY study population. CLINICAL TRIAL IDENTIFICATION NUMBER: LIBERTY 1, 2016-003727-27 (EudraCT) and NCT03049735; LIBERTY 2, 2016-005113-50 (EudraCT) and NCT03103087.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Catherino WH, Al-Hendy A, Zaim S, et al. Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2. Fertil Steril. 2025. PMID: 40320117. doi:10.1016/j.fertnstert.2025.04.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。